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Abstract 
Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of 
rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 
2008, provided the first evidence for the efficacy of sequential therapy for patients with 
metastatic clear cell renal cell carcinoma (RCC). In this study, everolimus was used after 
failure of one or several previous lines of therapy, and it demonstrated a 3-month survival 
benefit relative to placebo. Currently, based on the level 1 evidence, everolimus represents 
the molecule of choice for third-line therapy after failure of previous two tyrosine kinase 
inhibitors (TKIs). However, second-line use after failure of one TKI is challenged by two new 
molecules (nivolumab and cabozantinib), which proved to have better efficacy with similar 
toxicity profile. In non-clear cell metastatic RCC, the current evidence recommends 
everolimus as a second-line therapy after failure of previous first-line sunitinib. 
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Introduction
Renal cell carcinoma (RCC) is the 
seventh leading cancer among men and 
the tenth among women in the United 
States. In 2015, an estimated 61,560 
new cases of RCC were diagnosed in the 
United States (1).The pathogenesis of the 
dominant clear cell histological subtype 
of RCC is associated with a loss of the 
von Hippel-Lindau (VHL) gene function 
on chromosome 3p. The VHL tumor 
suppressor gene codes for VHL protein 
that regulates cellular response to 
hypoxia by targeting hypoxia-inducible 
factor. Inactivation of VHL leads to an 
increased blood vessel formation 
through the upregulation of angiogenic 
factors, such as vascular endothelial 
growth factor (VEGF), vascular 
endothelial growth factor receptor 
(VEGFR), platelet-derived growth factor 
receptor, and epidermal growth factor 
receptor (2). 
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Surgical treatment represents the standard 
of care in the management of localized RCC. 
However, up to 16% of patients present with 
de novo distant metastases at diagnosis, 
and about 30% of patients eventually 
develop metastases during follow-up (3). 
Historically, the median survival of patients 
with metastatic RCC (mRCC) has been 10 
months (4). The introduction of targeted 
therapies resulted in a paradigm shift in the 
management of this malignancy (5). The use 
of first-, second-, and subsequent-line 
targeted therapies resulted in up to 2-year 
increase in the life expectancy of patients 
with mRCC (6). Two subtypes of targeted 
therapies exist for the treatment of mRCC 
(tyrosine kinase inhibitor [TKI] and 
mammalian target of rapamycin inhibitors 
[mTORi]). Five TKIs (sunitinib, sorafenib, 
pazopanib, axitinib, and bevacizumab) and 
two mTORi (temsirolimus and everolimus) 
were approved for the treatment of mRCC 
(5, 7-12). Everolimus (RAD001) is an orally 
administered agent that inhibits the mTOR 
serine-threonine kinase. mTOR acts as a 
biological switch that regulates cellular 
metabolism, growth, and angiogenesis. In 
consequence, the disruption of mTOR 
pathway suppresses the progression of 
cancer cells through the inhibition of cell 
cycle and angiogenesis. 
A phase III trial on everolimus, published in 
2008, provided the first evidence for the 
efficacy of sequential therapy for patients with 
metastatic clear cell RCC, where everolimus 
was used after failure of one or several 
previous lines of therapy and demonstrated a 
3-month survival benefit relative to placebo 
(13). The practice of sequential therapy has 
since then become the standard of care. 
Today, not only everolimus but several other 
molecules are available for use in sequential 
fashion. Based on the alternative for second-
line therapy, the role of everolimus needs to 
be revised, and the objective of this review is 
to provide evidence supporting the optimal 
use of everolimus in the setting of metastatic 
clear cell RCC. To address this objective, 
evidence supporting its use either as first or 
subsequent line, as well as alone or in 
combination, is reviewed. 
Materials and methods 
A comprehensive PubMed literature search 
was performed for articles published 
between 2007 and 2015 using the key 
words “everolimus,” “RAD001,” “kidney,” 
and “renal cell carcinoma” in the PubMed 
library up to September 2015. Moreover, 
abstracts presented at the American 
Society of Clinical Oncology (ASCO) and the 
European Society of Medical Oncology 
(ESMO) annual meetings between the years 
2009 and 2015 were also retrieved. The 
search was limited to English literature, 
humans, and persons aged 18 years and 
older. The subject and outcome of interest, 
pertinence, quality, and details of reporting 
were the indicators of manuscript quality. 
Only data from phase II and III trials and 
expanded access program were included. 
Clinical efficacy of everolimus 
Data supporting sequential everolimus after 
failure of one or several previous treatment 
lines: RECORD-1 study 
The efficacy of everolimus in the 
management of metastatic clear cell RCC 
refractory to one or several lines of 
previous systemic therapy was confirmed 
in a multi-institutional phase III, placebo-
controlled trial (Renal Cell cancer 
treatment with Oral RAD001 given Daily 
[RECORD-1]). In this study, 410 patients 
were randomized to 10 mg/daily 
everolimus (n=272) or placebo and best 
supportive care (n=138). Most patients 
received multiple systemic agents that 
ranged from immunotherapy to cytotoxic 
chemotherapy prior to randomization with 
everolimus or placebo. The median 
progression-free survival (PFS) for 
everolimus was statistically superior to 
that for placebo and best supportive care 
(4.9 vs. 1.9 months; Hazard ration [HR]: 
0.33; P<0.001) (13). These data provided 
the first prospective and placebo-controlled 
evidence for the use of everolimus as a 
sequential therapy. Recommendation for 
specific second-line sequencing of this 
molecule was made upon publication (14). 
Its rationale was based on the lack of 
alternative data for specific second-line 
therapy from within randomized designs. 
Two additional features of this pivotal trial 
deserve mention (13, 15). First, less than 5% 
received first-line VEGF therapy that would 
reflect contemporary first-line use. In 46 
patients who were randomized to everolimus 
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or placebo after sunitinib failure, the 
recorded PFS benefit was 4.6 vs. 1.8 months. 
Second, as many as 26% of patients received 
two prior lines of VEGF-TKIs (sorafenib and 
sunitinib). Here, the benefit of everolimus 
given in second line was 5.4 vs. 1.9 months, 
relative to placebo. Unfortunately, the study 
included a marginal proportion of patients in 
whom everolimus was delivered in a second-
line setting, and even fewer specifically 
received first-line sunitinib. Nonetheless, the 
study provided excellent third-line and 
subsequent-line efficacy for everolimus 
because the vast majority (79%) of enrolled 
patients received multiple previous lines (16). 
The pivotal trial results were corroborated 
by population-based data from the 
everolimus expanded access program 
RAD001 expanded access clinical trial 
(REACT), where everolimus was offered to 
patients who progressed during initial 
VEGFR-TKI. In this study (n=1,367), 38.5% 
of patients received only one prior VEGFR-
TKI, whereas 31.6% received two prior 
VEGFR-TKI lines. In the REACT study, 
51.6 and 1.7% of patients treated with 
everolimus, respectively, achieved stable 
disease or partial remission at follow-up. 
Finally, 23.7% of patients progressed on 
everolimus (17). 
How to interpret the place of sequential 
everolimus in the era of the AXIS trial 
The findings of the RECORD-1 study, 
published in August 2008, revolutionized 
the management of mRCC (13). 
Specifically, they introduced the notion of 
sequential therapy and validated the 
efficacy of everolimus in this setting. In 
December 2011, Rini et al. (11) reported a 
phase III study comparing two alternative 
second-line therapies, axitinib vs. 
sorafenib, after failure of a single first-line 
therapy (sunitinib, cytokine, bevacizumab, 
and temsirolimus). Because of its design, 
the AXIS study distinguished itself from 
the RECORD-1 study. First and foremost, 
the sequential nature of the AXIS study 
design deserves mention: the sequencing 
was specifically and exclusively defined as 
second line. In contrast, in the RECORD-1 
study, only 21% of patients received 
everolimus as second line. Second, a 
smaller proportion received a targeted 
therapy as in first line and even fewer 
received first-line sunitinib, the established 
contemporary standard of care in first-line 
therapy (National Comprehensive Cancer 
Network [NCCN]). The vast majority of 
patients in the RECORD-1 study (79%) 
received everolimus as third or subsequent 
lines. In the AXIS study, all patients 
received sequential second-line therapy. 
Moreover, in the AXIS study, the majority 
of patients (54%) received first-line 
sunitinib, which is consistent with 
guideline recommendations and reflects 
the standard of care in clinical practice. 
Finally, it is of note that the potential 
benefit of an alternative mode of action 
(mTOR inhibition) of everolimus after 
failure of first-line VEGF-based therapy 
does not appear to represent an important 
argument favoring everolimus relative to a 
second-line VEGF-based therapy, such as 
axitinib. The relatively comparable median 
PFS of everolimus in second line vs. 
axitinib after sunitinib failure and 
numerous data from sequential VEGF-use 
studies, where the efficacy of sequential 
VEGF was confirmed, clearly support this 
contention (11, 18). 
In summary, robust data based on 79% of 
the RECORD-1 study cohort support the 
use of everolimus in third or subsequent 
lines. Conversely, the AXIS-1 study 
strongly supports the use of axitinib as 
second line, especially after failure of 
sunitinib. The sequence of first-line 
sunitinib, followed by second-line axitinib 
and eventually followed by third-line 
everolimus, appears most justified 
according to the existing data. Nonetheless, 
existing guidelines do not exclude the 
possibility of relying on second-line 
everolimus. 
Efficacy of everolimus as in first-line 
therapy: RECORD-3 study 
Based on the encouraging efficacy and 
tolerability of everolimus after failure of 
previous lines, a randomized, phase II 
noninferiority study was launched with the 
intent of challenging the established first-
line role of sunitinib in the setting of 
metastatic clear cell RCC (6). Specifically, 
the design postulated noninferiority of 
median combined PFS and/or of overall 
survival (OS) with the use of first-line 
everolimus followed by second-line 
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sunitinib (n=238 vs. the opposite sequence 
n=233). The majority of patients included 
displayed clear cell histological subtype 
(85%) and favorable or intermediate 
Memorial Sloan Kettering Cancer Center 
(MSKCC) prognosis (85%). The combined 
PFS medians were 21.1 vs. 25.8 months for 
the everolimus-sunitinib vs. sunitinib-
everolimus arm (HR: 1.3; 95% confidence 
interval [CI]: 0.9-1.7), respectively. The 
combined OS medians were 22.4 vs. 32.0 
months for the everolimus-sunitinib vs. 
sunitinib-everolimus arm (HR: 1.2; 95% CI: 
0.9-1.6), respectively. In consequence, the 
noninferiority of the proposed PFS and/or 
OS sequence of everolimus followed by 
sunitinib could not be supported. Therefore, 
the RECORD-3 data do not support the use 
of everolimus as first line instead of the 
established standard of care, sunitinib. 
First- or second-line everolimus combination 
therapy with bevacizumab: RECORD-2 study 
The concept of combining two agents with 
different mechanisms of action is attractive 
because it may offer greater efficacy and 
PFS. This premise was used to test the 
efficacy and tolerability of combined 
everolimus and bevacizumab (VEGF 
inhibitor) as either first-line or second-line 
therapies. Hainsworth et al. (19) addressed 
this hypothesis in a phase II study. Here, 
50 previously untreated and 30 treated 
patients were administered a combination 
of first-line everolimus and bevacizumab. 
The median first-line PFS was 9.1 months, 
the median second-line PFS was 7.1 
months, and toxicity profiles were very 
favorable. Based on these promising data, 
two large studies were designed to test this 
regimen (20). One was a large first-line, 
randomized phase II study comparing 
everolimus and bevacizumab regimen to 
bevacizumab and interferon regimen 
(RECORD-2 study). The other was a 
second-line, phase III post-sunitinib study 
comparing the same regimen to everolimus 
plus placebo. 
The phase II, open-label RECORD-2 trial 
randomized 365 treatment-naive mRCC 
patients to bevacizumab 10 mg/kg every 2 
weeks plus everolimus 10 mg/day or 
bevacizumab plus interferon alpha-2a 3-9 
MU three times/week. All patients had 
prior nephrectomy, and more than 90% 
had a good-to-intermediate MSKCC 
performance status. There was no 
significant difference between everolimus 
and interferon groups in objective response 
rates (27 vs. 28%) or median PFS based on 
central review (9.3 months vs. 10; HR: 
0.91; P=0.485) (20). The second study is 
still ongoing. It aims to compare the 
efficacy of everolimus combined with 
bevacizumab versus everolimus alone in 
second line after failure of previous 
sunitinib in patients with mRCC 
(NCT01198158). 
Head-to-head comparison in second- and 
subsequent-line use of everolimus 
In a phase II trial, Jonasch et al. (21) 
compared MK-2206, a selective inhibitor of 
phosphoinositide-3-phosphate kinase 
(PI3K), with everolimus in patients who had 
failed one or two prior VEGF inhibitors 
(n=43). Their results showed an inferior 
median PFS for MK-2206 compared to 
everolimus (3.65 vs. 7.43 months). 
Similarly, Powles et al. (22) compared the 
efficacy of second-line use of a PI3K/mTOR 
inhibitor (GDC-0980) to everolimus in 
patients with clear cell mRCC (n=85). Their 
analysis revealed that GDC-0980 was 
inferior to everolimus (median PFS: 3.7 vs. 
6.1 months; HR: 2.04; P<0.01). 
Two comparative phase III trials, aimed at 
exploring everolimus use in patients with 
clear cell mRCC who received one or two 
prior antiangiogenic agents, have been 
published recently (23, 24). The first study 
(METEOR) compared the efficacy of 
cabozantinib to everolimus in second and 
subsequent line after failure of previous 
TKI or cytokine therapy. Cabozantinib is a 
TKI that targets VEGFR, MET, and AXL. 
The latter two are associated with 
increased resistance to VEGFR inhibitors. 
The PFS and the interim OS analyses 
favored cabozantinib relative to everolimus. 
Specifically, the median PFS was 7.4 
months for cabozantinib vs. 3.8 months for 
everolimus (HR: 0.58; 95% confidence 
interval [CI]: 0.45-0.75; P<0.001). Both the 
molecules presented similar toxicity 
profiles. It is of note that 73% of patients 
were treated in second line and the 
remaining 27% represented third-line 
patients. In subgroup analyses, patients 
treated with second-line cabozantinib 
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showed better median PFS relative to 
everolimus (HR: 0.56; 95% CI: 0.42-0.75). A 
difference in PFS, albeit a nonsignificant one, 
was shown in individuals who represented 
third-line patients (HR: 0.67; 95% CI: 0.41-
1.1) (23). This observation implies that 
cabozantinib is better than everolimus in 
second but not necessarily in third line. 
The second phase III study compared 
nivolumab with everolimus in patients with 
clear cell mRCC, who were previously treated 
with one or two TKIs (sunitinib, pazopanib, 
and axitinib). Nivolumab is a human 
programmed death 1 (PD-1) receptor 
antibody that disrupted PD-1 and PD-ligand 
1 (PD-L1) signaling pathway, which resulted 
in increased antitumor immunity (24). The 
majority of study cohort (78%) represented 
second-line patients. The remainder 
represented third-line patients. The median 
OS was 25 months for nivolumab compared 
to 19.6 months for everolimus (HR: 0.73; 
P=0.002). However, no statistically significant 
differences were observed for median PFS 
between both arms (4.6 for nivolumab vs. 4.4 
months for everolimus; HR: 0.88; P=0.11). 
This observation implies that nivolumab may 
improve responses to subsequent agents, 
without demonstrating immediate PFS 
advantage relative to everolimus. Taken 
together, both studies show that novel 
molecules might provide better PFS or OS 
outcomes relative to everolimus. 
Data supporting the use of sequential 
everolimus after mTOR failure 
No level 1 evidence supports the use of 
sequential everolimus after failure of 
previous mTORi (temsirolimus). Indeed, 
previous temsirolimus use was an 
exclusion criterion for phase III trials. Maj-
Hes et al. (25) reported, in a retrospective 
study, on the use of everolimus as third or 
fourth line after failure of previous one or 
two TKI and one mTORi (temsirolimus). 
Seven patients were included in this study. 
The median PFS duration for everolimus 
after failure of previous temsirolimus was 
5.8 months. 
Efficacy of everolimus in non-clear cell 
mRCC 
Temsirolimus represents the standard of 
care for non-clear cell mRCC. Based on its 
established efficacy (9), Koh et al. (26) 
explored the efficacy of everolimus in 
patients with non-clear cell RCC. In their 
single-arm phase II trial (n=49), 59.2% 
(n=29) of patients had papillary subtype 
and the remaining 16.3% (n=8) patients 
had chromophobe RCC. First-line 
everolimus was used in 53.1% (n=26) of 
patients. In the remaining groups, 
everolimus was used as second line after 
the failure of prior sunitinib or sorafenib. 
In the first-line patients, everolimus use 
resulted in a median PFS of 3.7 months, 
whereas it was 5.3 months in the second 
line. 
Because the prognosis of patients with 
papillary mRCC was better than that of 
patients with other histological subtypes, a 
phase II study (RAPTOR) was designed to 
investigate the efficacy of first-line 
everolimus in patients with papillary 
mRCC. In this study (n=92), the median OS 
for first-line everolimus use was 21.1 
months. Specifically, the median OS for 
types 1 and 2 papillary mRCC were 28 and 
20.3 months, respectively (27). 
Recently, a randomized phase II trial 
(ESPN) compared the efficacy of first-line 
everolimus followed by second-line 
sunitinib versus first-line sunitinib 
followed by second-line everolimus in 
patients with non-clear cell mRCC (n=68). 
The majority were good or intermediate 
MSKCC risk. The median PFS for first-line 
sunitinib was 6.1 vs. 4.1 months for first-
line everolimus (P=0.25). Of all, 39 patients 
received second-line therapy. The median 
PFS for second-line sunitinib was 1.8 vs. 
4.3 months for second-line everolimus. The 
median OS recorded in patients exposed to 
first-line everolimus (10.5 months) was 
inferior to the OS recorded in patients 
exposed to first-line sunitinib (median OS 
not reached; P=0.01). In consequence, 
based on the OS inferiority recorded in the 
arm exposed to first-line everolimus and 
second-line sunitinib, the study was 
terminated (28). 
Finally, an ongoing phase II trial compares 
the efficacy of first-line everolimus vs. 
sunitinib in patients with non-clear cell 
mRCC (ASPEN trial). In this study, patients 
were stratified according to histological 
subtypes (papillary, chromophobe, and 
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unclassified) and MSKCC risk score (good, 
intermediate, and poor). The preliminary 
results showed that everolimus was better 
than sunitinib in patients with chromophobe 
histology (11.4 vs. 5.5 months) or poor 
MSKCC risk (6.1 vs. 4 months). Conversely, 
sunitinib was the preferred first-line 
molecule for papillary, unclassified histology, 
as well as for patients with good or 
intermediate MSKCC risk score (29). 
Based on the current evidence, everolimus is 
recommended as the second-line treatment 
in patients with non-clear cell mRCC after 
failure of previous first-line sunitinib. More 
studies are warranted to test its efficacy after 
failure of first-line temsirolimus in the non-
clear cell mRCC setting. 
Safety and tolerability 
Because patients with metastatic disease 
have limited life expectancy, assessment of 
everolimus toxicities is essential before 
treatment administration. The most 
common clinical toxicities in patients 
treated with everolimus for mRCC were 
stomatitis (44%), infections (37%), asthenia 
(33%), rash (29%), fatigue (31%), diarrhea 
(30%), and anorexia (25%). Of these, 
infectious complications (10%), stomatitis 
(4%), fatigue (5%), and pneumonitis (4%) 
represented G3-4 toxicities. The most 
frequent laboratory toxicities consisted of 
hypercholesterolemia (77%), anemia (92%), 
and hyperglycemia (57%). Of these, 
lymphopenia (18%), hyperglycemia (12%), 
and anemia (13%) represented G3-4 
toxicities (10). Comparable toxicity rates 
were found across all studies that assessed 
the clinical efficacy of everolimus in first or 
subsequent line in patients with mRCC 
(23, 24). It should be noted that 
everolimus-associated pneumonitis, 
stomatitis, as well as increased cholesterol 
and triglycerides levels, predicted better 
survival outcomes in patients with mRCC 
compared to patients who did not 
experience these adverse events: 
pneumonitis (median OS: 15.4 vs. 7.4 
months; P<0.001; HR: 0.32), stomatitis 
(median OS: 30.6 vs. 14 months; P=0.004), 
and hyperlipidemia (median OS: 26.4 vs. 
13.4 months; P=0.018) (30). 
Another important consideration in 
patients with mRCC is the change in 
patients’ quality of life after everolimus use. 
Using the everolimus phase III data, 
Beaumont et al. (31) used the Functional 
Assessment of Cancer Therapy Kidney 
Symptom Index- disease related symptoms 
(FKSI-DRS) and the European Organization 
for Research and Treatment of cancer 
(EORTC) QLQC30 as tools to assess 
patients’ quality of life before and after 
everolimus administration. They showed 
that patients treated with everolimus had 
comparable quality of life and physical 
functioning relative to patients treated with 
placebo and best supportive care. 
Conclusion 
Everolimus is the standard second- or third-
line therapy in patients with clear cell or non-
clear cell mRCC who failed prior VEGFR-TKI. 
However, its use in first line is not supported 
by evidence. Everolimus is well tolerated and 
is known for favorable acceptable rate of 
adverse events. Its place in the treatment 
paradigm of mRCC might be challenged by 
two emerging molecules (cabozantinib and 
nivolumab), which are tested in phase III 
trials. Moreover, comparative studies with the 
other second-line standard of care, for 
example, axitinib, are needed. 
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